Some retrospective and single-arm exploratory studies revealed that post-transplantation maintenance of other FLT3 inhibitors could also reduce relapse and improve survival for patients with FLT3-ITD AML [40, 41]. This evidence concerns the gene FLT3 and acute myeloid leukemia.